Hodgkin lymphoma (HL) is a potentially curable lymphoma, and modern therapy is expected to successfully cure more than 80% of the patients. Second-line salvage high-dose chemotherapy and autologous stem cell transplantation (auto-SCT) have an established role in the management of refractory and relapsed HL, leading to long-lasting responses in approximately 50% of relapsed patients and a minori...

Recent advances in Hodgkin lymphoma research are expected to prelude a promising new treatment era for patients and their treating physicians. Scientific investigations over the last few years have provided new insights into risk stratification, and, simultaneously, a plethora of novel targeted therapies are emerging for patients with relapsed and refractory disease. These novel therapies will ...

Mantle cell lymphoma (MCL) is an uncommon non-Hodgkin lymphoma with a heterogeneous natural history. Significant strides have been made in the management of MCL. Clinical follow-up exceeds a decade with long-term remission durations in some patients. Modern induction strategies employ rituximab; a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like backbone; and cytarabine (i...

Burkitt lymphoma and diffuse large B-cell lymphoma represent the majority of mature B-cell non-Hodgkin lymphomas in children, adolescents, and young adults. Although they are characterized by specific clinical and biological nuances, the 2 diseases share significant clinicopathologic overlap and are treated with the same chemotherapy regimens in pediatrics. Modern-day chemotherapy protocols ach...

The antibody-drug conjugate (ADC) cAC10-vcMMAE consists of the tubulin inhibitor monomethyl auristatin E (MMAE) conjugated to the chimeric anti-CD30 monoclonal antibody cAC10. This ADC potently interferes with the growth of CD30-positive haematological tumours, including Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma. This study found improved antitumour activity in a preclinical mode...

Phase 1 testing of SGN-30, a chimeric monoclonal antibody for the treatment of CD30(+) malignancies, was conducted in a multicenter study. To explore the safety profile and establish the maximum tolerated dose (MTD), 24 patients with refractory or relapsed Hodgkin lymphoma or CD30(+) non-Hodgkin lymphoma received 6 weekly doses of intravenous SGN-30 at 4 dose levels (2, 4, 8, or 12 mg/kg). Seru...

Although lymphomas are generally considered as tumors of lymph nodes about 25-40% arise at extranodal sites. We report a case of a 60 years old female who developed a right breast B-diffuse large cell non-Hodgkin lymphoma in 2005 treated by chemo/radio-therapy which relapsed at the same breast in 2007 and at the other breast in 2010. The patient underwent both radiologic and nuclear medicine st...

conclusions a high rate of 25% and 24.13% of hbv dna was detected among patients with hodgkin and non-hodgkin lymphoma, respectively. results three out of 12 (25%) hodgkin samples and seven out of 29 (24.13%) non-hodgkin showed positive hbv dna results. the results of sequencing revealed that the d genotype was predominant among the positive hbv patients. interestingly an unpredictable amino ac...

Extranodal natural killer/T-cell lymphoma (ENKL), nasal type, is a rare, aggressive non-Hodgkin lymphoma for which no clear standard of care has been established, particularly in the relapsed/refractory disease setting. Because of its rarity, randomized trials are not conducted specifically on ENKL, nasal type; however, case reports and small case series can provide important insights into pote...

non hodgkin lymphoma (nhl) constitutes 5% of all head & neck cancer. the incidence of it has been increased over the last four decades. one of main characteristic of nhl is extranodal presentation that has different pattern in various part of world. a retrospective was designed in a tertiary referral center. it has been done between january 1996 and march 2006. all clinical and pathological cha...